Collectively, these studies indicate that while VEGF-targeted combinations may not universally overcome ICI resistance, dual targeting of PD-1 and angiogenic pathways—especially through bispecific antibodies—represents a promising direction for future therapeutic development in resistant NSCLC. Here, PDCD1 is linked to non-small cell lung carcinoma.